Skip to main content
. 2022 Sep 12;13:5338. doi: 10.1038/s41467-022-33006-4

Fig. 2. Selective sRANKL inhibitor discovery and structure optimization.

Fig. 2

a The S3 chemical structure, activity, and binding affinity against sRANKL. OC: osteoclast; SPR: surface plasmon resonance. b The SPR curve of compound S3 and sRANKL complex. c Activity, binding affinity and solubility of S3-05 and S3-15. d The pharmacokinetic parameters of compound S3 and newly designed compounds S3-05 and S3-15.